LEADER 05166nam 22007335 450 001 9910678254303321 005 20251008142021.0 010 $a3-031-15848-2 024 7 $a10.1007/978-3-031-15848-3 035 $a(MiAaPQ)EBC7210728 035 $a(Au-PeEL)EBL7210728 035 $a(CKB)26240846800041 035 $a(DE-He213)978-3-031-15848-3 035 $a(PPN)269098232 035 $a(EXLCZ)9926240846800041 100 $a20230306d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMalarial Drug Delivery Systems $eAdvances in Treatment of Infectious Diseases /$fedited by Ranjita Shegokar, Yashwant Pathak 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (395 pages) 311 08$aPrint version: Shegokar, Ranjita Malarial Drug Delivery Systems Cham : Springer International Publishing AG,c2023 9783031158476 320 $aIncludes bibliographical references and index. 327 $aMalaria: Cellular Understanding of Disease -- Drug Resistance, Statistics and Patent Status -- Malaria: Current Treatment Options -- Polymeric Nanoparticles in Malaria -- Solid Lipid Nanoparticles in Malaria -- Dendrimers in Malaria -- Liposomes in Malaria -- Micro and Nano Emulsions in Malaria -- Nanosuspension in Malaria -- Alginate and Gelatin Nanoparticles in Malaria -- Niosomes in Malaria -- Metal Nanoparticles in Malaria -- Nanotechnology in Malaria Diagnosis -- Nanotechnology-based Vaccination -- Herbal Platforms in Malaria -- Surface-modified Drug Delivery Systems in Malaria,- Clinical Trials in Malaria -- Malaria-Overall Picture -- New Drugs in Synthesis Research for Malaria -- Disease Models In Malaria Research. 330 $aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity thatalmost always comes at the cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The theme of the first book is Malaria. This book compiles the complete road map of malarial drug delivery systems by understanding the pathophysiology of the disease, the current state of malaria across the globe, new clinical trials, emerging drugs, and the development of novel drug delivery platforms. Various novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of malarial research. 606 $aDrug delivery systems 606 $aNanobiotechnology 606 $aPharmaceutical chemistry 606 $aTropical medicine 606 $aPharmacology 606 $aMedical microbiology 606 $aDrug Delivery 606 $aNanobiotechnology 606 $aPharmaceutics 606 $aTropical Medicine 606 $aPharmacology 606 $aMedical Microbiology 615 0$aDrug delivery systems. 615 0$aNanobiotechnology. 615 0$aPharmaceutical chemistry. 615 0$aTropical medicine. 615 0$aPharmacology. 615 0$aMedical microbiology. 615 14$aDrug Delivery. 615 24$aNanobiotechnology. 615 24$aPharmaceutics. 615 24$aTropical Medicine. 615 24$aPharmacology. 615 24$aMedical Microbiology. 676 $a615.6 676 $a616.9362061 702 $aShegokar$b Ranjita 702 $aPathak$b Yashwant 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910678254303321 996 $aMalarial Drug Delivery Systems$93373336 997 $aUNINA